Sign In
Buy SGPYY
$42.52
+0.0600 (+0.141%)
At Close: Jun 23, 2026
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
10:09am, Wednesday, 02'nd Oct 2024
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK , Oct. 1, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities lawsuit.
Sage Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAGE
12:30pm, Tuesday, 01'st Oct 2024
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage"
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ:SAGE) and certain off
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit - SAGE
10:15am, Tuesday, 01'st Oct 2024
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics Lawsuit – SAGE
01:38pm, Monday, 30'th Sep 2024
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sage Therapeutics, Inc. ("Sage Therapeutics" or the "Company") (NASDAQ: SAGE) of a class action securities laws
The Schall Law Firm Invites Shareholder Participation In A Securities Fraud Case Against Sage Therapeutics Inc
11:00am, Monday, 30'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sa
According to THE SAGE GROUP, Less Than 20% of Symptomatic Peripheral Artery Disease (PAD) Patients Are Revascularized
10:54am, Monday, 30'th Sep 2024
BEAUFORT, S.C.--(BUSINESS WIRE)-- #CLIFighters--Recent research published by THE SAGE GROUP examined the number of PAD patients undergoing surgical bypass and endovascular revascularization in the U.S
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securiti
NEW YORK , Sept. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE).
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 a
